杭州九源基因生物医药股份有限公司（股票代码：02566，九源基因）于2026年7月13日公告，公司于香港联合交易所场内回购H股17,800股，占当日前已发行股本（不含库藏股）的约0.00741%。回购价格范围介乎每股6.06港元至6.34港元，综合平均回购价为6.112港元，涉资总额约10.88万港元。回购完成后，公司已发行股份总数保持245,398,800股，其中240,359,000股为已发行流通股，5,039,800股为库藏股。
根据公告，此次股份回购所依据的购回授权于2026年6月15日获股东大会批准，可回购股份数上限为24,151,640股。截至本次回购后，累计根据授权已回购1,157,400股，占授权通过当日已发行股本的约0.47922%。公司确认已遵守香港联合交易所证券上市规则及相关法律法规。本公告由公司联席公司秘书黄秀签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.